ClinicalTrials.gg
RecruitingNCT07265284Updated Dec 22, 2025

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of IBI112 and placebo in Psoriasis, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. Recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
120th of 182
104 · median 171
Started
2025
with 35 others
Phase 3
58 of 206
16 open now
Primary completion
2026-09
later than 30 of 65 live
Registered
178th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 120th largest by planned enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 58 in phase 3, reaches primary completion later than 30 of the 65 other live ones, and was the 178th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Males or females aged 12 to 18 years; Diagnosed with plaque psoriasis and a history of psoriasis ≥6 months; suitable for phototherapy and/or systemic treatment for psoriasis.

Exclusion criteria

Exclusion Criteria:

History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent Has received any conventional therapeutic agent within 1 months of the first administration of study agent Has received any topic therapeutic agent within 2 weeks of the first administration of study agent Hsa received IBI112

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    Participants receive placebo through week 16,placebo participants will cross over to receive IBI112 through week 44

    Drug: placebo

  • Experimental
    IBI112

    Participants receive IBI112 through week 44

    Drug: IBI112

Interventions

  • DrugIBI112

    IBI112 by subcutaneous injection

  • Drugplacebo

    placebo by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16

    PASI 75 is defined as at least a 75% reduction in PASI relative to baseline

    Time frame: week 16

  2. Percentage of patients achieving an static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) at Week 16

    sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.

    Time frame: week 16

Secondary outcomes

  1. Percentage of patients achieving PASI 50 at week 16

    PASI 50 is defined as at least a 50% reduction in PASI relative to baseline

    Time frame: week 16

  2. Percentage of patients achieving PASI 90 at week 16

    PASI 90 is defined as at least a 90% reduction in PASI relative to baseline

    Time frame: week 16

  3. Percentage of patients achieving PASI 100 at week 16

    PASI 100 is defined as at least a 100% reduction in PASI relative to baseline

    Time frame: week 16

  4. Percentage of patients achieving an sPGA 0 at week 16

    sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.

    Time frame: week 16

  5. Percentage of patients achieving an Children Dermatology life quality index (CDLQI) Score of 0 /1at week 16

    The CDLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life

    Time frame: week 16

  6. Percentage of patients achieving PASI 75 at week 56

    PASI 75 is defined as at least a 75% reduction in PASI relative to baseline

    Time frame: week 56

  7. Percentage of patients achieving PASI 90 at week 56

    PASI 90 is defined as at least a 90% reduction in PASI relative to baseline

    Time frame: week 56

  8. Percentage of patients achieving PASI 100 at week 56

    PASI 100 is defined as at least a 100% reduction in PASI relative to baseline

    Time frame: week 56

  9. Percentage of patients achieving an sPGA 0/1 at Week 56

    sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.

    Time frame: week 56

  10. Percentage of patients achieving an sPGA 0 at Week 56

    sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.

    Time frame: week 56

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2026, 9 months after the start.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 9 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 4, 2025
StartActual
Dec 3, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Jan 31, 2029
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07265284
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 3, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Dec 22, 2025

Study contacts

Bingjing Feng
Contact
bingjing.feng@innoventbio.com
+86 18361923769

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI112

Start the discussion